Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...

Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

Professor Ruth Plummer, Director of the Cancer Research UK Newcastle Centre, and Professor Herbie Newell, Emeritus Professor of Cancer Therapeutics at Newcastle University, were among the team, funded ...

can make Bendeka less effective rucaparib (Rubraca) — can increase the risk of side effects of Bendeka zafirlukast (Accolate) — can increase the risk of side effects of Bendeka In some cases ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

November 4, 2024 • How did life start on Earth? The answer is a big scientific mystery scientists are actively investigating. After talking with many scientists, host Regina G. Barber found that ...

Nov. 8, 2024 — Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if ...

Nov. 11, 2024 — Like the Earth, the Sun likely has swirling polar vortices, according to new research. But unlike on Earth, the formation and evolution of these vortices are driven by magnetic ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] Technology appraisal guidance TBC Rozanolixizumab for treating antibody-positive generalised ...